Theoretical exposure of chronically treated patients to lipid lowering agents

Pharmacoepidemiology and Drug Safety

Volumn 14, Issue 1, 2005, Pages 61-67

  Kucera, Zdenek ^a   Vlcek, Jiri ^a   Hejdova, Miroslava ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

Author keywords

Drug utilisation; Lipid lowering drugs; Pharmacoepidemiology; Prescription patterns

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BEZAFIBRATE; CERIVASTATIN; CIPROFIBRATE; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; CHRONIC PATIENT; CONTROLLED STUDY; CZECH REPUBLIC; DRUG DOSE REGIMEN; DRUG USE; EVIDENCE BASED MEDICINE; FEMALE; HEALTH INSURANCE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; PHARMACEUTICAL CARE; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

AGE FACTORS; ANTILIPEMIC AGENTS; CZECH REPUBLIC; DATA COLLECTION; DRUG ADMINISTRATION SCHEDULE; DRUG UTILIZATION REVIEW; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PHARMACOEPIDEMIOLOGY; SEX FACTORS; TIME FACTORS;

EID: 11844298423     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.1036     Document Type: Article

References (36)

1. Dawber TR. The Framingham Study: The Epidemiology of Atherosclerotic Disease. Harvard University Press: Cambridge, MA, USA, 1980.
2. Pooling Project Research Group. Relationship of blood pressure, serum cholesterol, smoking habits, relative weight and ECG abnormalities to incidence of major coronary events: final report of the Pooling Project. J Chronic Dis 1978; 31: 201-306.
3. Kannel WB, Neaton JD, Wentworth D, et al. Overall and coronary heart disease mortality rates in relation to major risk factors in 325 348 men screened for the MRFIT. multiple risk factor intervention trial. Am Heart J 1986; 112: 825-836.
4. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA 2001; 285: 2486-2497.
5. The lipid research clinics coronary primary prevention trial results - I: reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-364.
6. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333(20): 1301-1307.
7. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998; 279: 1615-1622.
8. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 439-446.
9. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
10. The Long-Term Intervention with Pravastatin in Ischaemic Heart Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
11. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360(9326): 7-22.
12. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341: 410-418.
13. BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 2000; 102: 21-27.
14. World Health Organization [online]. WHO Statistical Information System (WHOSIS). WHO Mortality Database. (Released 25 February 2003.) http://www3.who.int/whosis [cit. 9th of November, 2003].
15. Kari Kuulasmaa, Hugh Tunstall-Pedoe, Annette Dobson, et al. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA project populations. Lancet 2000; 355: 675-687.
16. Departeds 2000. ÚZIS ČR: Prague, Czech Republic, 2001; 96.
17. Cifkova R, Skodova Z, Lanska V, et al. Longitudinal trends of total cholesterol and HDL-cholesterol in the representative sample of Czech Republic population. Vnitr Lek 2000; 46: 501-505 [in Czech].
18. Poledne R, Skodova Z. Changes in nutrition, cholesterol concentration, and cardiovascular disease mortality in the Czech population in the past decade. Nutrition 2000; 16: 785-786.
19. Vlcek J, Macek K, Mullerova H, et al. Observation of lipid-lowering drugs consumption by means of Health Insurance Company Database. Ces a Slov Farm 2000; 49: 299-305 [in Czech].
20. ATC Index with DDDs. WHO Collaborating Centre for Drug Statistics Methodology: Oslo, Norway, 2001; 63-64.
21. Health Insurance Companies List [online]. Ministry of Health of the Czech Republic. http://www.mzcr.cz/data/c178/lib/zp-seznam.htm [cit. 9th of November, 2003].
22. Vlcek J, Kocova M, Kucera Z, et al. Využití database zdravotní pojištovny ke studii teoretické expozice hypolipidemiky. Vnitř Lék 2002; 48: 742-748.
23. West SL, Strom BL, Freundlich B, et al. Completeness of prescription recording in outpatient medical records from a health maintenance organization. J Clin Epidemiol 1994; 47: 165-171.
24. West SL, Savitz DA, Koch G, et al. Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol 1995; 142: 1103-1112.
25. Tsuyuki RT, Bungard TJ. Poor adherence with hypolipidemic drugs: a lost opportunity. Pharmacotherapy 2001; 21: 576-582.
26. Vestnik SUKL. SUKL (State Institute for Drug Control). Prague, Czech Republic, 2000.
27. Carvajal A, del Pozo JG, Rodriguez MB, et al. Utilization of lipid-lowering drugs in Spain between 1986 and 1998. Clin Drug Invest 2000; 20: 197-201.
28. Drug Consumption in Norway. Norsk Medisinaldepot ASA. Oslo, Norway, 1999.
29. Chen TJ, Lin SJ, Chen LK, et al. Prevalence of antilipemic drug use in Taiwan: analysis of a sampling cohort within the national health insurance. J Chin Med Assoc 2003; 66: 39-45.
30. Statistics on Drug Use in Australia 2002. Australian Institute for Health and Welfare. Canberra, Australia 2003. www.aihw.gov.au/publications/phe/sdua02/sdua02-c05.pdf [cit. 9th of November, 20031.
31. Krappweis J, Aumann D, Rentsch A, et al. The prescribing of lipid lowering drugs during a 1-year period: analysis of 7490 health insurance files. Pharmacoepidemiol Drug Safe 2000; 9 119-125.
32. Larsen J, Vaccheri A, Andersen M, et al. Lack of adherence to lipid-lowering drug treatment. A comparison of utilization patterns in defined populations in Funen, Denmark and Bologna, Italy. Br J Clin Pharmacol 2000; 49: 463-471.
33. Martikainen J, Klaukka T, Reunanen A, et al. Recent trends in the consumption of lipid-lowering drugs in Finland. J Clin Epidemiol 1996; 49: 1453-1457.
34. Magrini N, Einarson T, Vaccheri A, et al. Use of lipid-lowering drugs from 1990 to 1994: an international comparison among Australia, Finland, Italy (Emilia Romagna Region), Norway and Sweden. Eur J Clin Pharmacol 1997; 53: 185-189.
35. Ceska R, Cifkova R, Poledne R, et al. Recommendations for treatment of hyperlipoproteinemia in adult patients made by Czech Society for Atherosclerosis. Casopis Lekaru Ceskych 1997; 136: 257-261.
36. Treatment and prevention of coronary heart disease by lowering serum cholesterol levels. Dutch Institute for Healthcare Improvement (CBO): Utrecht, Netherlands, 1998.